Novartis AGFRA:NOT0 83 Buyback Yield % is 2.81 as of Jul. 02, 2026, which is 3% below its 10-year median of 2.90. GuruFocus rates FRA:NOT0 with a GF Score™ of 83/100 and a GF Value™ of €15.09 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 292 Drug Manufacturers companies, Novartis AG ranks better than 93.15% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Novartis AG's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NOT0 vs LLY, JNJ, ABBV: Buyback Yield % Comparison
For the Drug Manufacturers - General subindustry, Novartis AG's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novartis AG Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Novartis AG's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novartis AG (FRA:NOT0) has a Buyback Yield % of 2.81 as of Jul. 02, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Novartis AG and its competitors. This is near median its historical median of 2.90. Over the past decade, Novartis AG's Buyback Yield % has ranged from 0.58 to 6.27. According to the industry distribution chart, Novartis AG ranks #20 out of 292 companies in the Drug Manufacturers industry, placing it in the top 6.8%.
Is Novartis AG's Buyback Yield % too high?
Novartis AG's current Buyback Yield % of 2.81 is near median its 10-year median of 2.90. Over the past 10 years, this metric has ranged from a low of 0.58 to a high of 6.27. Based on the distribution chart, Novartis AG ranks #20 out of 292 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Novartis AG has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's Buyback Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novartis AG ranks #20 out of 292 companies for Buyback Yield %. This places Novartis AG in the top 7% of its industry — outperforming the majority of peers. Historically, Novartis AG's own Buyback Yield % has ranged from 0.58 to 6.27 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Novartis AG and its competitors. Novartis AG's current Buyback Yield % is 2.81, which is near median its own 10-year median of 2.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Based on GuruFocus' analysis, Novartis AG (FRA:NOT0) is currently considered Modestly Overvalued. The stock's GF Value™ is €15.09, compared to a current price of €18.20 — trading 20.6% above its estimated fair value. The current Buyback Yield % is 2.81, which is near median its 10-year median of 2.90. Novartis AG's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Novartis AG (FRA:NOT0), the current Buyback Yield % is 2.81 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novartis AG (FRA:NOT0) Overvalued in 2026?
Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued.
The current stock price of €18.20 is trading 20.6% above its estimated GF Value™ of €15.09.
GuruFocus considers Novartis AG to be Modestly Overvalued.
Key valuation signals for FRA:NOT0:
Buyback Yield %: 2.81 (near median its 10-year median of 2.90)
GF Value™: €15.09 vs. price of €18.20 (20.6% above fair value)
No single metric tells the full story. See the FRA:NOT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
83GF Score
Get the complete analysis for FRA:NOT0
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NOT0 has been successfully added to your 
